NRIXHIGH SIGNALOPERATIONAL10-K

NRIX has completely rebranded its lead drug pipeline, replacing NX-5948 and NX-2127 with bexobrutideg and zelebrudomide, while advancing to a potentially pivotal Phase 2 trial.

This represents a fundamental shift in the company's clinical strategy, moving from early-stage Phase 1 studies to a potentially pivotal Phase 2 trial for bexobrutideg that could support Accelerated Approval. The complete rebranding of lead candidates suggests either significant reformulations or a strategic repositioning of the pipeline, which creates both opportunity for faster regulatory approval and uncertainty about the continuity of previous clinical data.

Comparing 2026-01-28 vs 2025-01-28View on EDGAR →
FINANCIAL ANALYSIS

NRIX shows strong financial momentum with cash more than doubling to $247M and revenue nearly doubling to $77M, providing substantial runway for operations. However, R&D expenses increased 43% to $317M and operating cash burn worsened 45% to -$250M, reflecting the company's aggressive investment in advancing its rebranded pipeline. The improved cash position appears driven by partnership revenues, but the significantly higher burn rate indicates investors should monitor runway sustainability despite the current strong balance sheet.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+124.5%
$110.0M$247.0M

Cash position surged 124.5% — strong cash generation or capital raise providing significant financial cushion.

Revenue
P&L
+99.3%
$38.6M$77.0M

Strong top-line growth of 99.3% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
+51%
$9.3M$14.0M

Capital expenditure jumped 51% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
-44.5%
-$172.6M-$249.5M

Operating cash flow fell 44.5% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+43%
$221.6M$316.9M

R&D investment increased 43% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-36.6%
-$193.6M-$264.5M

Net income declined 36.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-34.1%
-$213.0M-$285.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

LANGUAGE CHANGES
NEW — 2026-01-28
PRIOR — 2025-01-28
ADDED
As of January 23, 2026, the Registrant had 102,843,012 shares of common stock, $0.001 par value per share, outstanding.
Our lead drug candidates, bexobrutideg, zelebrudomide and NX-1607, are in the early stages of clinical development.
We have received Orphan Drug Designation for bexobrutideg and may seek Orphan Drug Designation for other drug candidates in the future.
Our partnered drug discovery pipeline consists of a clinical stage degrader of IRAK4 (NX-0479/GS-6791), a preclinical stage degrader of STAT6, currently in investigational new drug application (IND), enabling studies, and multiple currently undisclosed targets under collaboration agreements with Gilead Sciences, Inc.
Status of Bexobrutideg: We are currently conducting a Phase 2 study of bexobrutideg in patients with relapsed or refractory CLL having failed three previous lines of therapy, specifically a covalent BTK inhibitor (cBTKi), a BCL2 inhibitor (BCL2i) and a non-covalent BTK inhibitor (ncBTKi).
+7 more — sign up free →
REMOVED
As of January 24, 2025, the Registrant had 75,886,817 shares of common stock, $0.001 par value per share, outstanding.
Our lead drug candidates, NX-5948, NX-2127 and NX-1607, are in the early stages of clinical development.
Our partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4, STAT6 and multiple currently undisclosed targets under collaboration agreements with Gilead Sciences, Inc.
Status of NX-5948: We are currently conducting a Phase 1b cohort expansion study of NX-5948 in patients with relapsed or refractory B-cell malignancies.
Food and Drug Administration (FDA) granted Fast Track designation for NX-5948 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →